NEW YORK and LONDON, June 13, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced …
Notice of Annual General Meeting of Shareholders (AGM) to be held on June 30, 2022
NOTICE OF GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 30, 2022 PROXY FORM (CLICK TO VIEW AND DOWNLOAD) ANNUAL REPORT AND CONSOLIDATED FINANCIAL …
Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting
NEW YORK and LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced …
Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress
Clinical trial sites open and enrolling patients in FDA and EMA registration-directed Phase III Part A study of nomacopan in pediatric hematopoietic stem cell …
Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting
NEW YORK and LONDON, May 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company …
